CRISPR Screen Dataset
Doench JG (2016) - 1-PMID26780180
Title: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.
Screen Details:
- Screen Rationale : Increased drug resistance
- Cell Type : Melanoma Cell Line [BTO:0000849]
- Cell Line : A-375 [BTO:0002806, CELLOSAURUS:CVCL_0132]
- Phenotype : Response To Chemicals
- Condition : Vemurafenib (2 µM) [ChEBI]
- Library : Avana | Type: CRISPRn | Format: Pool | Enzyme: Cas9 | Methodology: Knockout
- Analysis Method : STARS | Number of Hits: 94 | Full Dataset Size: 18,675
- Experimental Setup : Drug Exposure | Duration: 14 Days | MOI: < 1
- Significance : Authors have indicated that results with Score.2 (FDR) < 0.1 are to be considered significant. These results are indicated by '' in the HIT column of the table below.
Notes:
- With the Avana library screened in lentiCRISPRv2, 94 genes showed vemurafenib resistance (A-375 cells; STARS analysis at FDR < 10%).
Score Distribution
< 21.21128123
> 0.65129933